SLC5A2 and diabetes mellitus: Research indicates that metformin therapy, by reducing pericoronary fat levels, contributes to improved cardiovascular outcomes through the diminution of inflammatory markers, SGLT2, and leptin levels in individuals with pre-diabetes [205].